MANF Delivery for Age-Related Skeletal Muscle Regeneration

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Age-related decline in skeletal muscle regeneration is attributed to a decline in Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF) levels, leading to impaired muscle repair and regeneration.

Innovation Solution

Increasing the concentration of MANF in skeletal muscle through administration of MANF, nucleic acids encoding MANF, or cells expressing MANF to promote muscle regeneration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If MANF concentration is increased in skeletal muscle, then muscle regeneration is enhanced, but the complexity of treatment protocols increases

Engineering Contradiction:

Improvemuscle regeneration rateVSAvoidtreatment protocol complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent applies parameter changes by modulating the concentration of MANF protein in skeletal muscle through controlled administration of MANF-containing compositions. This involves adjusting dosage, frequency, and timing of treatments to optimize regeneration while managing complexity. The patent specifically addresses age-related decline in MANF levels, using parameter modulation to restore regenerative capacity without requiring complex multi-component therapies.

Inventive Principle:

Principle #35Parameter changes

2Quantity of substance

If MANF levels are increased to promote regeneration, then new myofiber density increases, but the risk of improper tissue remodeling increases

Engineering Contradiction:

Improvenew myofiber densityVSAvoidtissue remodeling quality

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The patent incorporates feedback mechanisms by monitoring the phenotypic transition of macrophages and the formation of new myofibers during treatment. The MANF-containing compositions are administered in a controlled manner, with adjustments based on the tissue's regenerative response. This feedback loop ensures that new myofiber formation is promoted while preventing improper tissue remodeling, as the treatment protocol adapts to the specific needs and progress of each patient's muscle regeneration.

Inventive Principle:

Principle #23Feedback

3Productivity

If MANF concentration is increased in aged individuals, then regenerative capacity is restored, but the duration of treatment required increases

Engineering Contradiction:

Improveregenerative capacityVSAvoidtreatment duration

Core Design Contradiction:

ProductivityVSDuration of action of moving object

Solution Approach 1:

The patent applies preliminary action by administering MANF-containing compositions at specific time points before and during the muscle injury or disease process. This preventive and early intervention approach aims to restore regenerative capacity before significant damage occurs, potentially reducing the overall treatment duration needed. The patent specifically targets age-related decline, using preliminary MANF administration to establish regenerative pathways before the natural aging process fully impairs muscle repair capabilities.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS20260027182A1Mesencephalic astrocyte-derived neurotrophic factor (MANF) for increasing muscle regeneration

Publication Date: 2026.01.29 GULBENKIAN INSTITUTE FOR MOLECULAR MEDICINE

AI summary

This invention relates to methods for increasing the regeneration of a skeletal muscle that comprise increasing the concentration of Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF) in the skeletal muscle. The concentration of MANF may be increased by administering to the individual MANF, a nucleic acid encoding MANF, or a cell expressing MANF. This may be useful in the treatment of skeletal muscle damage or disease, for example in individuals with an age-related reduction in skeletal muscle regenerative capacity.